Mohammad Vaziri Shares Breakthrough Insights on Factor XI Inhibitors for Thrombosis Prevention and Safer Anticoagulation
Mohammad Vaziri, Thoracic Surgery Professional at IRAN University of Medical Sciences (IUMS), posted on LinkedIn:
”Key points
Factor XI (FXI) inhibitors aim to uncouple hemostasis from thrombosis, presenting a novel approach to anticoagulation, with a reduced risk of bleeding compared with that associated with traditional anticoagulant agents.
Several phase II studies indicate that FXI inhibitors decrease thrombotic complications dose-dependently, without corresponding increases in bleeding, suggesting a favourable safety profile.
FXI inhibitors showed non-inferiority and potential superiority to low-molecular-weight heparin for the prevention of venous thromboembolism in patients undergoing orthopaedic surgery, with minimal bleeding risks observed at therapeutic doses.
Milvexian and abelacimab are theoretically promising for reducing the risk of bleeding associated with thromboprophylaxis in patients with atrial fibrillation; phase III clinical trials of safety and efficacy are ongoing.
In phase II trials involving patients with non-cardioembolic ischaemic stroke, no significant benefit of FXI inhibitors was found in terms of the primary ischaemic end points, but future phase III trials might find benefits in selected patients with large-vessel atherosclerosis.
The ongoing LIBREXIA-ACS trial will assess the use of milvexian in 16,000 patients with recent acute coronary syndrome.”
Reaf the full article here.
Title: Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism
Authors: Davide Capodanno, John H. Alexander, M. Cecilia Bahit, John W. Eikelboom, C. Michael Gibson, Shaun G. Goodman, Vijay Kunadian, Gregory Y. H. Lip, Renato D. Lopes, Roxana Mehran, Shamir R. Mehta, Manesh R. Patel, Jonathan P. Piccini, Sunil V. Rao, Christian T. Ruff, P. Gabriel Steg, Jeffrey I. Weitz, Dominick J. Angiolillo
Stay updated with Hemostasis Today.
-
May 11, 2026, 15:54Elena Coniuhov: Bringing Together a Strong Laboratory, Diagnostics and Life Sciences Community
-
May 11, 2026, 15:54The First Move Happens Before Surgery Even Begins – Let’s Talk Patient Blood Management
-
May 11, 2026, 15:48Roberta Gualtierotti: Modern Approaches to Diagnosis and Treatment of Hemophilia A and B
-
May 11, 2026, 15:42Tareq Abadl: Massive Transfusion – The Hidden Citrate Risk
-
May 11, 2026, 15:36Sonal Sonu: The Global Crisis of Blood Donation
-
May 11, 2026, 15:28Does New DIC Terminology Improve Clarity or Increase Confusion?- JTH
-
May 11, 2026, 15:19Chokri Ben Lamine: Sepsis Induced Coagulopathy Is Not a Single Disease Phenotype
-
May 11, 2026, 15:10William Wallace: Why Vitamin C Is the Only Reason Your Collagen Doesn’t Melt at Body Temperature
-
May 11, 2026, 14:44World Thalassaemia Day: Building Care Around Patients – Novo Nordisk Haemophilia and Haemoglobinopathies Foundation